Aldeyra Therapeutics (ALDX)

Executive Summary

Aldeyra Therapeutics is a clinical-stage biotechnology company pioneering a novel class of medicines that trap Reactive Aldehyde Species (RASP), a root cause of inflammation in immune-mediated diseases. The company's lead product candidate, reproxalap, is a first-in-class RASP inhibitor in late-stage development for ophthalmic indications, including dry eye disease and allergic conjunctivitis. Reproxalap has demonstrated statistically significant improvements in patient-reported symptoms and clinical signs across multiple Phase 3 trials, positioning it as a potential non-steroidal alternative to existing therapies. Additionally, Aldeyra is advancing ADX-2191 (intravitreal methotrexate) for proliferative vitreoretinopathy (PVR), a rare retinal disorder with no approved treatments, and has an early-stage systemic pipeline targeting conditions such as asthma and Sjögren-Larsson syndrome. With a strong intellectual property portfolio and a focused strategy on high-need inflammatory diseases, Aldeyra represents a compelling investment opportunity in the ophthalmology and immunology space. The company's near-term value is driven by regulatory milestones for reproxalap, while longer-term upside depends on pipeline expansion and potential partnerships.

Upcoming Catalysts (preview)

• Q4 2026FDA decision on reproxalap NDA for dry eye disease60% success
• Q3 2026Top-line data from Phase 3 trial of reproxalap for allergic conjunctivitis75% success
• Q1 2027Initiation of Phase 2/3 trial of ADX-2191 for proliferative vitreoretinopathy80% success